

## Results of Extraordinary General Meeting

---

**1 May 2025**

**Melbourne, Australia, 1 May 2025:** Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) is pleased to advise that all resolutions put to today’s Extraordinary General Meeting were passed on a poll by the requisite majorities in accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), details of the poll voting results and proxy votes for the resolutions are attached.

**–ENDS–**

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Investor Relations

[investor.relations@4dmedical.com](mailto:investor.relations@4dmedical.com)

#### Administration

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

### About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical’s innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company’s FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical’s solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio’s AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical’s mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)

EXTRAORDINARY GENERAL MEETING  
Thursday, 1 May, 2025RESULT OF EXTRAORDINARY  
GENERAL MEETING (ASX REPORT)

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
01	RATIFICATION OF ISSUE OF SHARES UNDER THE PLACEMENT	NA	9,070,440 73.17%	1,616,376 13.04%	1,710,182 13.80%	868,730	76,560,494 97.93%	1,616,376 2.07%	868,730	Carried
02	APPROVAL OF PROPOSED ISSUE OF NEW OPTIONS UNDER THE PLACEMENT OPTIONS OFFER AND SPP OPTIONS OFFER	NA	4,224,908 67.12%	1,328,193 21.10%	741,872 11.79%	887,167	70,676,652 98.16%	1,328,193 1.84%	887,167	Carried
03	RATIFICATION OF PROPOSED ISSUE OF NEW OPTIONS TO SUB-UNDERWRITERS	NA	12,486,813 76.53%	2,163,982 13.26%	1,665,386 10.21%	2,343,629	79,888,364 97.36%	2,163,982 2.64%	2,387,336	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item